Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population

Original Article

Abstract

Background and purpose

Ankylosing spondylitis (AS) is a kind of rheumatic disease, leading to pain, fatigue, stiffness, and functional impairment, which seriously affects the quality of life. Etanercept, a fully human recombinant protein, has been applied for the treatment of AS. However, there has not been a systematic analysis for its efficacy and safety.

Methods

This meta-analysis of fourteen randomized, double-blind, placebo-controlled clinical trials with 1,570 participants was performed to investigate the efficacy and safety of etanercept, by means of calculating the overall relative risk, and to compare the different responses between the Caucasian population and the Chinese population.

Results

Generally, there was sufficient evidence to prove that etanercept has its advantages in both disease activity controlling and symptoms relieving, especially for axial joints compared with peripheric joints, without higher incidence of serious adverse events.

Interpretation

Our preliminary analysis provided that the Caucasian population has better response to etanercept treatment, with more treatment-emergent adverse events. Further specially designed clinical trials need to be performed to investigate the different responses between axial and peripheric joints, also between different races.

Keywords

Ankylosing spondylitis Etanercept Meta-analysis 

Notes

Conflict of interest

None.

References

  1. 1.
    Braun J, Khan MA, Sieper J (2000) Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response? Ann Rheum Dis 59:985–994PubMedCrossRefGoogle Scholar
  2. 2.
    Braun J, Bollow M, Sieper J (1998) Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 24:697–735PubMedCrossRefGoogle Scholar
  3. 3.
    Carter ET, McKenna CH, Brian DD, Kurland LT (1979) Epidemiology of ankylosing spondylitis in Rochester, Minnesota, 1935–1973. Arthritis Rheum 22:365–370PubMedCrossRefGoogle Scholar
  4. 4.
    Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J (2003) Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23:61–66PubMedGoogle Scholar
  5. 5.
    Ward MM, Reveille JD, Learch TJ, Davis JC Jr, Weisman MH (2008) Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis. Arthritis Rheum 59:822–832PubMedCrossRefGoogle Scholar
  6. 6.
    Ward MM, Reveille JD, Learch TJ, Davis JC Jr, Weisman MH (2008) Impact of ankylosing spondylitis on work and family life: comparisons with the US population. Arthritis Rheum 59:497–503PubMedCrossRefGoogle Scholar
  7. 7.
    Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B et al (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442–452PubMedCrossRefGoogle Scholar
  8. 8.
    Toussirot E, Wendling D (1998) Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 56:225–240PubMedCrossRefGoogle Scholar
  9. 9.
    Arend WP (2002) The mode of action of cytokine inhibitors. J Rheumatol Suppl 65:16–21PubMedGoogle Scholar
  10. 10.
    Fernandez-Botran R (2000) Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs 9:497–514PubMedCrossRefGoogle Scholar
  11. 11.
    Gratacós J, Collado A, Filella X, Sanmartí R, Cañete J, Llena J, Molina R, Ballesta A, Muñoz-Gómez J (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33(10):927–931PubMedCrossRefGoogle Scholar
  12. 12.
    Francois RJ, Neure L, Sieper J, Braun J (2006) Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumor necrosis factor in two patients with early disease and transforming growth factor in three more advanced cases. Ann Rheum Dis 65:713–720PubMedCrossRefGoogle Scholar
  13. 13.
    Fernandez-Botran R (2000) Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs 9:497–514PubMedCrossRefGoogle Scholar
  14. 14.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48(6):1667–1675PubMedCrossRefGoogle Scholar
  15. 15.
    Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187–1193PubMedCrossRefGoogle Scholar
  16. 16.
    Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R et al (2005) Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years. Heumatology 44:670–676Google Scholar
  17. 17.
    Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G et al (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 67:340–345PubMedCrossRefGoogle Scholar
  18. 18.
    Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230–3236PubMedCrossRefGoogle Scholar
  19. 19.
    Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ et al (2008) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67:346–352PubMedCrossRefGoogle Scholar
  20. 20.
    Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H et al (2006) Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 54:678–681PubMedCrossRefGoogle Scholar
  21. 21.
    Barkham N, Coates LC, Keen H, Hensor E, Fraser A, Redmond A, Cawkwell L, Emery P (2010) Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 69(11):1926–1928 Epub 2010 May 28PubMedCrossRefGoogle Scholar
  22. 22.
    Van der Heijde D, Landewé R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC Jr (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58(5):1324–1331PubMedCrossRefGoogle Scholar
  23. 23.
    Rychly DJ, Dipiro JT (2005) Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25(9):1181–1192PubMedCrossRefGoogle Scholar
  24. 24.
    Askling J, Forted CM, Baecklund E et al (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumor necrosis factor antagonists. Ann Rheum Dis 64(10):1414–1420PubMedCrossRefGoogle Scholar
  25. 25.
    Moher D, Cook DJ, Eastwood S et al (1999) Improving the quality of reports of meta-analysis of randomised controlled trials: the QUOROM statement. Lancet 354:1896–1900PubMedCrossRefGoogle Scholar
  26. 26.
    Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12PubMedCrossRefGoogle Scholar
  27. 27.
    Higgins JPT, Green S (2008) Cochrane handbook for systematic reviews of interventions version 5.0.1 [updated September 2008]. The Cochrane CollaborationGoogle Scholar
  28. 28.
    Simunovic N, Sprague S, Bhandari M (2009) Methodological issues in systematic reviews and meta-analyses of observational studies in orthopaedic research. J Bone Joint Surg [Am] 91:87–94CrossRefGoogle Scholar
  29. 29.
    Gorman JD, Sack KE, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346(18):1349–1356PubMedCrossRefGoogle Scholar
  30. 30.
    Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63(12):1594–1600PubMedCrossRefGoogle Scholar
  31. 31.
    Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P et al (2011) Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 70(5):799–804PubMedCrossRefGoogle Scholar
  32. 32.
    Van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X et al (2006) Etanercept study 314 investigators. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65(12):1572–1577PubMedCrossRefGoogle Scholar
  33. 33.
    Huang Feng, Zhang Jie, Huang JL, Wu DH, Li ZG, Chen SL et al (2010) A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis. Chin J Intern Med 49(9):741–745Google Scholar
  34. 34.
    Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T et al (2005) Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 32(10):1911–1917PubMedGoogle Scholar
  35. 35.
    Wanders AJ, Gorman JD, Davis JC, Landewe RB, van der Heijde DM (2004) Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. Arthritis Rheum 51(1):1–8PubMedCrossRefGoogle Scholar
  36. 36.
    Wang LS, Huang F, Zhang JL, Deng XH, Zhang YM, Zhang LY et al (2007) A cohort analysis of safety tumor necrosis factor-α antagonists in the treatment of Chinese patients with ankylosing spondylitis. Chin J New Drugs 16(7):556–561Google Scholar
  37. 37.
    Zhang H, Deng XH, Zhang YM, Zhang JL, Huang F (2008) Studies on safety of etanercept in treatment of ankylosing spondylitis. Adverse Drug React J 10(6):396–399Google Scholar
  38. 38.
    Zhang YM, Li XL, Wu HL, Zhang J (2009) Short-term safety of etanercept therapy in patients with ankylosing spondylitis. Chin J Drug Appl Monit 6(1):4–13Google Scholar
  39. 39.
    Zhang J (2010) Initiatory approach on clinical assessment and evaluation of etanercept in the treatment of ankylosing spondylitis. Graduation dissertation for Master’s degreeGoogle Scholar
  40. 40.
    Braun J, Golder W, Bollow M, Sieper J, van der Heijde D (2002) Imaging and scoring in ankylosing spondylitis. Clin Exp Rheumatol 20:S178–S184PubMedGoogle Scholar
  41. 41.
    Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M et al (2005) Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 44(3):342–348PubMedCrossRefGoogle Scholar
  42. 42.
    Baraliakos X, Brandt J, Listing J, Haibel H, Sorensen H, Rudwaleit M et al (2005) Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 53:856–863PubMedCrossRefGoogle Scholar
  43. 43.
    Baraliakos X, Davis J, Tsuji W, Braun J (2005) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor receptor fusion protein etanercept. Arthritis Rheum 52:1216–1223PubMedCrossRefGoogle Scholar
  44. 44.
    Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P, for the ASSERT Study Group et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54:1646–1652PubMedCrossRefGoogle Scholar
  45. 45.
    McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al (2007) Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 11(28):1–158, iii–ivGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Zhi-han Li
    • 1
  • Yang Zhang
    • 1
  • Jian Wang
    • 1
  • Zhan-jun Shi
    • 1
  1. 1.Department of Orthopaedic SurgeryNanfang HospitalGuangzhouChina

Personalised recommendations